CMCecilia Martini

Cecilia Martini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cecilia Martini has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Light-Induced Therapies for Prostate Cancer Treatment

    by Claudia Ferroni, Alberto Del Rio, Cecilia Martini, Elisabetta Manoni, Greta Varchi

    Prostate cancer (PC) is one of the most widespread tumors affecting the urinary system and the fifth-leading cause from cancer death in men worldwide. Despite PC mortality rates have been decreasing during the last years, most likely due to an intensification of early diagnosis, still more than 300,000 men die each year because of this disease. In this view, researchers in all countries are engaged in finding new ways to tackle PC, including the design and synthesis of novel molecular and macromolecular entities able to challenge different PC biological targets, while limiting the extent of unwanted side effects that significantly limit men's life quality. Among this field of research, photo-induced therapies, such as photodynamic and photothermal therapies (PDT and PTT), might represent an important advancement in PC treatment due to their extremely localized and controlled cytotoxic effect, as well as their low incidence of side effects and tumor resistance occurrence. Based on these considerations, this review aims to gather and discuss the last 5-years literature reports dealing with the synthesis and biological activity of molecular conjugates and nano-platforms for photo-induced therapies as co-adjuvant or combined therapeutic modalities for the treatment of localized PC.


  • 2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis

    by Fernanda P. Pons-Faudoa, Antons Sizovs, Nicola Di Trani, Jesus Paez-Mayorga, Giacomo Bruno, Jessica Rhudy, Madhuri Manohar, Kevin Gwenden, Cecilia Martini, Corrine Ying Xuan Chua, et al.


  • Intercalation of Bioactive Molecules into Nanosized ZnAl Hydrotalcites for Combined Chemo and Photo Cancer Treatment

    by Cecilia Martini, Claudia Ferroni, Marzia Bruna Gariboldi, Anna Donnadio, Annalisa Aluigi, Giovanna Sotgiu, Fabiola Liscio, Paolo Dambruoso, Maria Luisa Navacchia, Tamara Posati, et al.

    Hydrotalcites-like compounds, also known as anionic clays or layered double hydroxides, represent the only example of lamellar solid with positively charged layers and exchangeable interlayer anions. In this study, a nanostructured HTlc with formula [Zn0.72Al0.28(OH)2] Br0.28·0.69 H2O was used as inorganic drug delivery system for anticancer therapy. Two different molecules were selected for being separately intercalated into ZnAl-HTlc: the anticancer drug norcantharidin, known for inducing cell cycle arrest at G2/M phase, and the tetra-sulfonated aluminum phthalocyanine, a photosensitizer used in anticancer photodynamic therapy (PDT). The obtained hybrid ZnAl-HTlc, were characterized in terms of X-ray powder diffraction pattern, thermogravimetric analysis, SEM microscopy, drug release profile, in vitro cytotoxicity, and ability to produce ROS and 1O2 upon light irradiation. Our results clearly indicate that the two selected compounds are efficiently intercalated within HTlc layers. Moreover, in vitro preliminary studies on a panel of cancer cells lines account for a greater cytotoxicity of the two drugs once loaded on HTlc either when administrated singularly or in combination. In addition, the analysis of the synergistic effect of the two formulations was evaluated by determining their combination index, which showed a greater cytotoxicity when using as a 1:2 ratio of HTlc@Al-Ftl and HTlc@NCTD, respectively.


  • Chlorin e6 keratin nanoparticles for photodynamic anticancer therapy

    by A. Aluigi, G. Sotgiu, C. Ferroni, S. Duchi, E. Lucarelli, C. Martini, T. Posati, A. Guerrini, M. Ballestri, F. Corticelli, et al.

    This work describes the preparation of keratin and chlorin e6-conjugated keratin nanoparticles, KNPs and KNPs@Ce6 respectively, by comparing self-assembling and desolvation methodologies. Nanoparticles were characterized in terms of yield, size, morphology, Ce6 loading ratio and ability to produce reactive oxygen species (ROS) upon irradiation with white light. Overall, both methods provided nanoparticles of comparable dimensions, morphology and Ce6 loading ratio. KNPs@Ce6 obtained by a self-assembling procedure were able to produce ROS in a concentration and irradiation-time dependent manner, while displaying compelling evidence of their photostability. In vitro internalization and photo-toxicity studies were performed on osteosarcoma (U2OS) and glioblastoma (U87) cells lines to assess the ability of KNPs@Ce6 nanoparticles to act as delivery systems for photodynamic therapy of cancer. Importantly, at all the Ce6 considered concentrations, e.g. 0.5, 2.5 and 5.0 μg mL−1, no dark toxicity was detected while the amount of Ce6 inside the cells, significantly increased when loaded onto KNPs. The irradiation of tumor cells loaded with KNPs@Ce6 resulted in a greater cell death percentage (approximately 90%) as compared to free Ce6 in both cell types and at all the considered concentrations, thus showing KNPs as effective and promising delivery vehicles for photodynamic therapy applications.